Progen gets in synth

By Dylan Bushell-Embling
Wednesday, 02 July, 2008

Brisbane biotech Progen Pharmaceuticals (ASX: PGL) has spun out its manufacturing business into a wholly-owned subsidiary.

The new subsidiary will be called PharmaSynth, and will be responsible for completing Progen's PI-88 manufacturing process.

It will also offer process development and manufacturing services to the biotechnology industry.

Progen's former director of manufacturing operations, Les Tillack, is the new company's CEO.

Positive results for H5 avian influenza (bird flu) have been confirmed in two seabirds found in...

Designed to support Australia's homegrown life sciences innovation, AusBiotech has announced...

After the WHO determined the outbreak of Ebola in the DRC and Uganda to be a public health...

Content from other channels on our network

Tapping into the labour mobility market to fill ongoing workforce gaps

NSW cracks down on illegal tanning with first two successful prosecutions

Australian hospital workers' mobile phones carry deadly superbugs — study reveals

Bupa to acquire Partnered Health's 68 primary care and three urgent care clinics

The Data-Ready Foundation for an AI-Powered Healthcare Future

Testing beef trim sampling cloths for Escherichia coli O157:H7, STEC, and Salmonella species with harmonised enrichments

PhD opportunity in functional snack food innovation

Aseptic, minimal processing and flexible lines on show in 2027

Breaking the biofilm shield that harbours foodborne pathogens

Second cell-cultured food under assessment by FSANZ

Siemens announces AI-enabled software grant to UniSC

Deakin University launches metal resources research centre

Dragos introduces OT-native cybersecurity AI

Construction begins on south‍-‍west WA advanced manufacturing hub

Newcastle carbon capture plant opens